Skip to search formSkip to main contentSkip to account menu

Anti-PD1 Monoclonal Antibody PDR001

Known as: PDR001 
A fully humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors
Background: NIZ985 is a soluble IL-15/IL-15 receptor α heterodimer (hetIL-15) that binds IL-2/IL-15 receptor β/γ and promotes… 
2019
2019
Non-islet cell tumour hypoglycaemia in a patient with a well-differentiated gastric neuroendocrine tumour
A 61-year-old man, without noteworthy medical history, presented with complaints of progressive fatigue and flushes. Diagnostic… 
2018
2018
Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy…
Introduction: The phase 3 COMBI-i study (NCT02967692) is evaluating spartalizumab (S; PDR001) in combination with dabrafenib… 
2018
2018
Abstract CT175: Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumors
Background: Dysregulated Wnt/β-catenin signaling has been linked to several cancers, including pancreatic cancer (PC) and… 
2018
2018
A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
TPS2616Background: Spartalizumab is an immunoglobulin G4 humanized monoclonal antibody that binds with subnanomolar affinity to… 
2017
2017
P2.04-013 ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
2017
2017
1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated…
E. Gasal, A.M. Arance Fernandez, P.A. Ascierto, V. Atkinson, R. Dummer, K.T. Flaherty, J-J. Grob, J. Hansson, J. Hassel, J… 
2017
2017
PS04.05 ElevatION NET 201:Ph II Study of PDR001 in Metastatic, Well Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly Differentiated GEP NEC: Topic: Medical Oncology
2016
2016
A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.
3060Background: PDR001 is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. PDR001 binds to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)